Thromboelastometry profile in children with beta-thalassemia


Turhan A. B., BÖR Ö., Akay O. M., Akgun N. A.

INTERNATIONAL JOURNAL OF HEMATOLOGY, cilt.99, sa.4, ss.407-412, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 99 Sayı: 4
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1007/s12185-014-1546-6
  • Dergi Adı: INTERNATIONAL JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.407-412
  • Anahtar Kelimeler: Thromboelastometry, Thalassemia, Thrombosis, Children, TISSUE FACTOR ACTIVATION, HYPERCOAGULABLE STATE, VEIN THROMBOSIS, BLOOD, INTERMEDIA, PLATELETS, PLASMA
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Beta (beta)-thalassemia is characterized by a hypercoagulable state and an increased risk of thrombosis, which can result in significant morbidity and mortality. The coagulation pattern and determinants of thrombosis in patients with beta-thalassemia remain largely unknown. The aim of this study was to evaluate the whole blood thromboelastometry (TEM) profile of beta-thalassemic children by ROTEMA (R). ROTEMA (R) assays (INTEM, EXTEM) and traditional coagulation parameters (platelet count, prothrombin time, activated partial thromboplastin time, and fibrinogen) were performed on blood samples from 17 subjects with beta-thalassemia and 19 non-thalassemic controls. Maximum clot firmness (MCF) was significantly higher in subjects with beta-thalassemia than in controls on EXTEM and INTEM analysis (p < 0.001 and p < 0.001, respectively). Of the patients with beta-thalassemia, MCF was higher and clot formation time was shorter in splenectomized subjects than in non-splenectomized subjects on EXTEM and INTEM (p = 0.026, p = 0.002, p < 0.001, p < 0.001, respectively). TEM profiles in beta-thalassemic children were more hypercoagulable compared with controls. Larger prospective studies are needed to evaluate the relevance of the association between ROTEMA (R) profile and thromboembolic events in patients with beta-thalassemia.